Glycoengineering

Glycoengineering encompasses strategies deliberately modifying glycosylation patterns of therapeutic proteins through genetic manipulation of biosynthetic pathways, culture condition optimisation, or enzymatic remodelling to achieve desired functional properties including enhanced efficacy, extended half-life, reduced immunogenicity, or improved manufacturability.

The biopharmaceutical industry applies glycoengineering producing next-generation biologics with improved characteristics. Antibody glycoengineering modifies Fc glycans enhancing antibody-dependent cellular cytotoxicity, achieved by eliminating fucose from glycans. Cell line engineering employs gene knockouts, knock-ins, or expression optimisation modulating glycosyltransferases and glycosidases controlling glycan structures. Process optimisation adjusts culture parameters including pH, temperature, dissolved oxygen, and feeding strategies influencing glycosylation patterns. In vitro enzymatic remodelling treats purified proteins achieving homogeneous, optimised glycoforms. Analytical methods characterise glycoengineered products ensuring desired modifications, absence of unwanted glycans, and consistency across manufacturing batches. As competition intensifies in biologics markets, glycoengineering continues advancing enabling precise glycan control.